Marked suppression of stimulated gastric acid and pepsin secretion by enisoprost, a new PGE<sub>1</sub> analogue

SUMMARYThe gastric antisecretory effects of three different doses of enisoprost, a new synthetic PGE1 analogue, were compared with placebo and misoprostol in 20 healthy male volunteers. Enisoprost 100, 200 and 400 μg all significantly (P < 0.0001; ANOVA) suppressed histamine‐stimulated acid and pepsin output when compared with placebo or misoprostol 200 μg. Misoprostol produced a significant decrease of stimulated acid output when compared with placebo (P= 0.0012). The concentration of pepsin in gastric juice was significantly (P < 0.0001) decreased by enisoprost at the commencement of histamine stimulation. This effect was short‐lived, and was maximal with enisoprost 400 μg. There was a significant dose‐response relationship for enisoprost for inhibition of stimulated acid output (P= 0.0065). Enisoprost was well tolerated, and no consistent drug‐related adverse effects were detected. The profile of antisecretory effect of enisoprost, producing marked suppersion of both acid and pepsin secretion independently, is unusual. This combination of activity along with any mucosal protective properties might be particular effective in the treatment of peptic ulcer disease.

Marked suppression of stimulated gastric acid and pepsin secretion by enisoprost, a new PGE₁ analogue Journal Articles